A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
Phase of Trial: Phase III
Latest Information Update: 08 Oct 2017
At a glance
- Drugs Octreotide (Primary)
- Indications Acromegaly
- Focus Registrational; Therapeutic Use
- Acronyms OPTIMAL
- Sponsors Chiasma
- 31 Aug 2017 Status changed from not yet recruiting to recruiting.
- 27 Aug 2017 Planned End Date changed from 30 May 2020 to 1 May 2020.
- 27 Aug 2017 Planned primary completion date changed from 31 Dec 2019 to 1 Dec 2019.